Board

Henrik Stender

Henrik Stender joined the board of ViroGates in august 2020.
Owner of Stender Diagnostics.

Education: M.Sc. in Chemical Engineering and Ph.D. in Immunology from Technical University of Denmark; B. Comm. in Business Informatics and Economics, Copenhagen Business School.

Competencies: 30 years of international experience with all aspects of development of innovative in vitro diagnostic (IVD) medical devices improving patient care; strong track-record of regulatory approvals, incl. +20 U.S. FDA clearances, covering infectious diseases, immune-monitoring and cancer; broad range of scientific management positions; inventor; founder; board member.

Directorships: • Visiopharm A/S (BM)

Shareholdings: Shares: 0, Warrants (vested): 0 (30 September 2020)

Henrik is independent of the issuer, major shareholders and senior management.

Lars Krogsgaard

Lars Krogsgaard joined the board of ViroGates in April 2016.
Professional board member and investor

Education: B.Sc. in Economics, Copenhagen Business School; MBA in Finance and International Business, Stern School of Business, New York.

Competencies: Track-record as active investor, owner and board member in more than 25 Nordic companies incl. other growth companies; strategic development; business development; risk management; financing, M&A.

Directorships: • Daintel ApS (BM) • DCR Solutions A/S (BM) • Forward Capital A/S (BM, M)
• 4AM ApS (M) • Samplix A/S (MB) • 6AM ApS (M)

Shareholdings: Shares: 325,965, Warrants (vested): 0 (30 September 2020)

Lars is not an independent director.

Jørgen Thorball

Jørgen Thorball founded ViroGates with Jesper Eugen-Olsen and Peter Benson in 2001.
Managing Partner at XOventure GmbH

Education: MD, University of Copenhagen

Competencies: Life science entrepreneur and founder of several companies, many of them based on his own medical inventions; management and board positions in listed blue-chip pharma companies; financing; M&A.

Directorships: • 3Brain AG (C) • BioMe AS (BM) • Retipharma A/S (BM) • Rigi Care (M)

Shareholdings: Shares: 10,204, Warrants (vested): 20,139 (30 September 2020)

Jørgen is independent of the issuer, major shareholders and senior management.

Lars Kongsbak

Lars Kongsbak joined ViroGates in February 2015 as Chairman of the Board.
President and CEO of Samplix ApS

Education: M.Sc. in Biology, Copenhagen University; Ph.D. in molecular biology from the Technical University of Denmark (DTU)

Competencies: Former President & CEO of listed biopharmaceutical company; strategic business development; M&A; financing, broad-based leadership experience; senior scientist positions at blue-chip companies.

Directorships: • BlueBee Holding BV (BM)

Shareholdings: Shares: 6,968, Warrants (vested): 37,070 (30 September 2020)

Lars is independent of the issuer, major shareholders and senior management.

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates